BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCompany update

Presentations to underscore Allocetra TM 's novel mechanism targeting immune imbalance in joint disease

Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it...

Related news

ENLVEnlivex Therapeutics2026-07-13 13:00 EST

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-06-15 13:00 EST

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

ELTXElicio Therapeutics, Inc.2026-08-24 12:00 EST

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

HOWLWerewolf Therapeutics2026-08-21 12:00 EST

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

MDNAMedicenna Therapeutics Corp.2026-08-14 11:00 EST

Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences

APVOAptevo Therapeutics2026-08-13 20:05 EST

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

APVOAptevo Therapeutics2026-08-12 13:30 EST

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

ELTXElicio Therapeutics, Inc.2026-08-10 12:00 EST

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

RNACCartesian Therapeutics2026-08-07 11:00 EST

Cartesian Therapeutics Announces New Employment Inducement Grants

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States